Nuria Barbarroja

Biographical Sketch
NamePosition title
Nuria Barbarroja Postdoctoral researcher, Miguel Servert
Institution and locationDegreeYear(s)Field of study
University of Cordoba, Spain BsC 2000 Biology
University of Cordoba, Spain PhD 2006 Biomedicine
A. Positions and Honors

Position

  • 2001-2006 Predoctoral fellowship, Reina Sofía Hospital. Cordoba, Spain
  • 2006-2008 Postdoctoral fellowship, Joseph Carreras International foundation. Reina Sofia Hospital. Cordoba, Spain
  • 2009-2010 Postdoctoral contract (Sara Borrell, Fund for Health Research of the Ministry of Health Carlos II). Virgen de la Victoria hospital, Malaga, Spain
  • 2010-2012 Postdoctoral researcher. Institute Metabolic Science, Cambridge University, UK.
  • 20012-2013 Postdoctoral contract (Sara Borrell grant holder, Fund for Health Research of the Ministry of Health Carlos II). Virgen de la Victoria hospital, Malaga, Spain
  • 2013-2015 Postdoctoral researcher. University of Cordoba, IMIBIC. Cordoba, Spain
  • 2016-currently Postdoctoral researcher, Miguel Servet grant holder, Fund for Health Research of the Ministry of Health Carlos III, IMIBIC, Cordoba, Spain.

Other experience and profesional memberships

  • 2003- Member, Spanish society of Hematology
    2014- Member, Spanish society of Rheumatology
    2007-2014 Member, PAIDI CTS-234 group
    2009- Member, Ciberobn, pathophysiology of the obesity 2014- Member, PAIDI CTS-1004 group

Honors

  • 2006 Joseph Carreras International Foundation award
    2006. IV National award of investigation from the Foundation of the Physicians College.
    2009. Prize from the Spanish Society of Thrombosis and Haemostasis.
    2012. Award from the IMIBIC to the most relevant scientific publication of the year.
    2013. XI National award of investigation from the Foundation of the Physicians College.
    2015. Award from the IMIBIC to the most relevant scientific publication of the year
    2015. Award from the IMIBIC to the most relevant scientific publication of the year in collaboration with international groups
B. Brief summary of relevant clinical research experience
  • PARTICIPATION IN RESEARCH PROJECTS.- I have participated in 25 research projects (national and international)
  • Presentations in Congresses.- 91 abstracts presented at national and international meetings
  • Awards obtained- 13 from diverse international and national organizations
  • PATENTS AND UTILITY MODELS.- 3 (P201630725; P201630628; EP14382178.3) H index: 14

     

  • SCIENTIFIC PUBLICATIONS. Peer-reviewed Publications.- 42 publications :

    1. Ruiz-Limón P, Ortega R, Arias de la Rosa I, Abalos-Aguilera MC, Perez-Sanchez  C, Jiménez-Gómez Y, Peralbo-Santaella E, Font P, Ruiz-Vilchez D, Ferrin G, Collantes-Estevez E, Escudero A, López-Pedrera Ch and Barbarroja N. Tocilizumab improves the pro-atherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis and inflammation. Transl Res. 2016 Dec 9. Pii: S1931-5244(16)30423-6.
    2. Jamin C, Le Lann L, Alvarez-Errico D, Barbarroja N, Cantaert T, Ducreux J, Dufour AM, Gerl V, Kniesch K, Neves E, Trombetta E, Alarcón-Riquelme M, Marañon C, Pers JO. Multi-center harmonization of flow cytometers in the context of the European "PRECISESADS" project. Autoimmun Rev. 2016 Nov;15(11):1038-1045. doi: 10.1016/j.autrev.2016.07.034.
    3. Perez-Sanchez  C, Aguirre MA, Ruiz-Limón P, Barbarroja N, Jiménez-Gómez Y, de la Rosa IA, Rodruiguez-Ariza A, Collantes-Estévez E, Segui P, Velasco F, Cuadrado MJ, Teruel R, González-Conejero R, Martínez C, López-Pedrera Ch. Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus erythematosus patients. Sci Rep. 2016 Aug 9;6:31375.
    4. López-Pedrera C*, Barbarroja N*, Jimenez-Gomez Y, Collantes-Estevez E, Aguirre MA, Cuadrado MJ. Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches.  Rheumatology (Oxford). 2016 Dec;55(12):2096-2108. Review. *Shared first authorship
    5. López-Pedrera Ch, Aguirre MA, Ruiz-Limon P, Perez-Sanchez C, Jimenez-Gomez Y, Barbarroja N , Cuadrado MJ. Immunotherapy in antiphospholipid síndrome. Int Immunopharmacol. 2015 Aug;27(2):200-8.
    6. Castro-Villegas C, Perez-Sanchez C, Escudero A, Filipescu I, Verdu M, Ruiz-Limón P, Aguirre MA, Jiménez-Gomez Y, Font P, Rodriguez-Ariza A, Peinado JR, Collantes-Estévez E, González-Conejero R, Martinez C, Barbarroja N*, López-Pedrera Ch*. Circulating miRNAs as potential biomarkers of therapy effectiveness in Rheumatoid Arthritis patients treated with anti-TNFα. Arthritis Res Ther. 2015 Mar. 9;17:49. *Shared senior authorship.
    7. Barbarroja N, Rodriguez-Cuenca S, Nygren H, Camargo A, Pirraco A, Relat J, Cuadrado I, Pellegrinelli V, Medina-Gomez G, Lopez-Pedrera C, Tinahones FJ, Symons JD, Summers SA, Oresic M, Vidal-Puig A. Increased dihydroceramide/ceramide ratio mediated by defective expression of degs1 impairs adipocyte differentiation and function.Diabetes. 2015 Apr;64(4):1180-92
    8. Rodriguez-Cuenca S, Barbarroja N, Vidal-Puig A. Dihydroceramide desaturase 1, the gatekeeper of ceramide induced lipotoxicity. Biochim Biophys Acta. 2015 Jan;1851(1):40-50. Review. *Shared first authorship
    9. .Barbarroja N, Pérez-Sanchez C, Ruiz-Limon P, Castro-Villegas C, Aguirre MA, Carretero R, Segui P, Jimenez-Gomez Y, Sanna M, Rodriguez-Ariza A, Collantes-Estevez E, Escudero A, López-Pedrera C. Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2706-16.
    10. Ruiz-Limon P*, Barbarroja N*, Perez-Sanchez C, Aguirre MA, Bertolaccini ML, Khamashta MA, Rodriguez-Ariza A, Almadén Y, Segui P, Khraiwesh H, Gonzalez-Reyes JA, Villalba JM, Collantes-Estevez E, Cuadrado MJ, Lopez-Pedrera C. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. Ann Rheum Dis. 2015 Jul;74(7):1450-8. *These authors equally collaborated in this work
    11. Perez-Sanchez C*, Barbarroja N*, Messineo S, Ruiz-Limon P, Rodriguez-Ariza A, Jimenez-Gomez Y, Khamashta MA, Collantes-Estevez E, Cuadrado MJ, Aguirre MA, Lopez-Pedrera C. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis. 2015 Jul;74(7):1441-9.  *These authors equally collaborated in this work
    12. Carobbio S, Hagen RM, Lelliott CJ, Slawik M, Medina-Gomez G, Tan CY, Sicard A, Atherton HJ, Barbarroja N, Bjursell M, Bohlooly-Y M, Virtue S, Tuthill A, Lefai E, Laville M, Wu T, Considine RV, Vidal H, Langin D, Oresic M, Tinahones FJ, Fernandez-Real JM, Griffin JL, Sethi JK, López M, Vidal-Puig A. Adaptive changes of the Insig1/SREBP1/SCD1 set point help adipose tissue to cope with increased storage demands of obesity. Diabetes. 2013 Nov;62(11):3697-708.
    13. Tinahones FJ, Coin Araguez L, Murri M, Oliva Olivera W, Mayas Torres MD, Barbarroja N, Gomez Huelgas R, Malagon MM, El Bekay R. Caspase induction and BCL2 inhibition in human adipose tissue: a potential relationship with insulin signaling alteration. Diabetes Care. 2013 Mar; 36(3):513-21
    14. Barbarroja N, Lopez-Pedrera C, Garrido-Sanchez L, Mayas MD, Oliva-Olivera W, Bernal-Lopez MR, El Bekay R, Tinahones FJ. Progression from high insulin resistance to type 2 diabetes does not entail additional visceral adipose tissue inflammation. PLoS One. 2012;7(10):e48155.
    15. Camacho A, Rodriguez-Cuenca S, Blount M, Prieur X, Barbarroja N, Fuller M, Hardingham GE, Vidal-Puig A. Ablation of PGC1 beta prevents mTOR dependent endoplasmic reticulum stress response. Exp Neurol. 2012 Oct; 237(2):396-406
    16. Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, Bertolaccini ML, Khamashta MA, Rodriguez-Ariza A, Segui P, Collantes-Estevez E, Barbarroja N, Khraiwesh H, Gonzalez-Reyes JA, Villalba JM, Velasco F, Cuadrado MJ, Lopez-Pedrera Ch. Mitochondrial dysfunction in Antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. Blood. 2012 Jun 14; 119(24):5859-70
    17. Rodriguez-Cuenca S, Carobbio S, Velagapudi VR, Barbarroja N, Moreno-Navarrete JM, Tinahones FJ, Fernandez-Real JM, Oresic M, Vidal-Puig A. Peroxisome Proliferator-Activated Receptor γ-Dependent Regulation of Lipolytic Nodes and Metabolic Flexibility. Mol Cell Biol. 2012 Apr;32(8):1555-65.
    18. Lopez-Pedrera C, Ruiz-Limon P, Valverde-Estepa A, Barbarroja N, Rodriguez-Ariza A. To cardiovascular disease and beyond: new therapeutic perspectives of statins in autoimmune diseases and cancer. Curr Drug Targets. 2012 ; 13(6):829-41
    19. Prieur X, Mok CY, Velagapudi VR, Nunez V, Fuentes L, Montaner D, Ishikawa K, Camacho A, Barbarroja N, O'Rahilly S, Sethi JK, Dopazo J, Orešič M, Ricote M, Vidal-Puig A. Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophag lipotoxicity and M2/M1 polarization in obese mice. Diabetes. 2011 Mar;60(3):797-809. Epub 2011 Jan 24.
    20. Lopez-Pedrera C, Ruiz-Limon P, Aguirre MA, Barbarroja N, Perez-Sanchez C, Buendia P, Rodriguez-Garcia IC, Rodriguez-Ariza A, Collantes-Estevez E, Velasco F, Khasmahta M, Cuadrado MJ. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis. 2011 Apr; 70(4):675-82.
    21. Rodriguez-Ariza A, Lopez-Pedrera C, Aranda E, Barbarroja N. VEGF targeted therapy in acute myeloid leukemia. Crit Rev Oncol Hematol. 2011 Nov;80(2):241-56. doi: 10.1016/j.critrevonc.2010.09.009. Epub 2010 Oct 29. Review.
    22. Lopez-Pedrera C, Aguirre MA, Barbarroja N, Cuadrado MJ. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotechnol. 2010; 2010. pii: 607084. Epub 2010 Sep 26.
    23. Barbarroja N, Lopez-Pedrera R, Mayas MD, Garcia-Fuentes E, Garrido-Sanchez L, Macias-Gonzalez M, El Bekay R, Vidal-Puig A, Tinahones FJ. The obese healthy paradox: is inflammation the answer? Biochem J. 2010 Aug 15;430(1):141-9.
    24. Gonzalez-Aragon D, Alcain FJ, Ariza J, Jodar L, Barbarroja N, Lopez-Pedrera C, Villalba JM. ES936 stimulates DNA synthesis in HeLa cells independently on NAD(P)H:quinone oxidoreductase 1 inhibition, through a mechanism involving p38 MAPK. Chem Biol Interact. 2010 Jul 30; 186(2):174-83
    25. Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, Lopez-Pedrera C. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia. Exp Hematol. 2010 Aug; 38(8):641-52. Epub 2010 Apr 7.
    26. Cuadrado MJ, Aguirre MA, Barbarroja N, Khamashta MA, Lopez-Pedrera Ch. Proteomics in antiphospholipid syndrome: a review. Lupus. 2010 Apr;19(4):385-8.
    27. Lopez-Pedrera C, Aguirre MA, Buendia P, Barbarroja N, Ruiz-Limon P, Collantes-Estevez E, Velasco F, Khamashta M, Cuadrado MJ. Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome. Arthritis Rheum. 2010 Mar; 62(3):869-77.
    28. Barbarroja N, Torres LA, Luque MJ, Carretero RM, Valverde-Estepa A, Lopez-Sanchez LM, Rodriguez-Ariza A, Velasco F, Torres A, Lopez-Pedrera C. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia. Exp Hematol. 2009 Jun;37 (6):679-91
    29. Torres LA, Barbarroja N, Dorado G, Velasco F, Lopez-Pedrera C. VEGF/KDR loop is a target of AG1296 in acute myeloid leukaemia showing FLT3-internal tandem duplications. Br J Haematol. 2009 Jun; 145(6):836-8.
    30. Lopez-Pedrera C, Barbarroja N, Aguirre MA, Torres LA, Velasco F, Cuadrado MJ. Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases. Lupus. 2008 Oct;17(10):904-15
    31. Lopez-Pedrera C, Cuadrado MJ, Herandez V, Buendia P, Aguirre MA, Barbarroja N, Torres LA, Villalba JM, Velasco F, Khamashta M. Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis. Arthritis Rheum. 2008 Sep;58(9):2835-44
    32. Barbarroja N, Velasco F, Lopez-Pedrera C. [Intracellular mechanisms involved in the angiogenic process in hematological malignancies]. Med Clin (Barc). 2008 Apr 26;130(15):585-90
    33. Barbarroja N, Siendones E, Torres LA, Luque MJ, Martinez JM, Dorado G, Velasco F, Torres A, Lopez- Pedrera C. MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia. Br J Haematol. 2008 Jul;142(1):27-35. Epub 2008 Apr 28.
    34. Barbarroja N, Aristides-Torres L, Hernandez V, Martin C, Dorado G, Torres A, Velasco F, Lopez-Pedrera C. Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia. Leuk Lymphoma. 2007 Jun; 48(6):1187-99
    35. Siendones E, Barbarroja N, Torres LA, Buendia P, Velasco F, Dorado G, Torres A, Lopez-Pedrera C. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematol Oncol. 2007 Mar; 25(1):30-7
    36. Cuadrado MJ, Buendia P, Velasco F, Aguirre MA, Barbarroja N, Torres LA, Khamashta M, Lopez-Pedrera C. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost. 2006 Nov;4(11):2461-9
    37. Lopez-Pedrera C, Barbarroja N, Dorado G, Siendones E, Velasco F. Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies. Leukemia. 2006 Aug; 20(8):1331-40. Epub 2006 May 25.
    38. Lopez-Pedrera C, Villalba JM, Siendones E, Barbarroja N, Gomez-Diaz C, Rodriguez-Ariza A, Buendia P, Torres A, Velasco F. Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets. Proteomics. 2006 Apr;6 Suppl 1:S293-9
    39. Lopez-Pedrera C, Buendia P, Barbarroja N, Siendones E, Velasco F, Cuadrado MJ. Antiphospholipidmediated thrombosis: interplay between anticardiolipin antibodies and vascular cells. Clin Appl Thromb Hemost. 2006 Jan;12(1):41-5
    40. Lopez-Pedrera C, Buendia P, Cuadrado MJ, Siendones E, Aguirre MA, Barbarroja N, Montiel-Duarte C, Torres A, Khamashta M, Velasco F. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum. 2006 Jan;54 (1):301-11
    41. López-Pedrera C, Barbarroja N, Buendía P, Torres A, Dorado G, Velasco F. Promyelocytic leukemia retinoid signaling targets regulate apoptosis, tissue factor and thrombomodulin expression. Haematologica. 2004 Mar; 89(3):286-95.
    42. López-Pedrera C, Barbarroja N, Velasco F. Pathogenic mechanisms of thrombosis in neoplasia: therapeutic implications. Med Clin (Barc). 2004 Feb 14;122(5):190-6.